Summary Data from a completed randomized trial in breast cancer are used to demonstrate and quantify the variation in estimated survival curves and log-rank statistics at different times throughout a trial. False 'plateaux' are common, as are wide fluctuations in x2 values obtained from the log-rank test when there are few events. We show how analyses conducted at different times can demonstrate different effects. Long follow-up is often necessary to allow correct interpretation of results. We discuss the assumption of proportional hazards and the consequences of making that assumption inappropriately. We show how checking whether hazards are proportional can help in avoiding erroneous conclusions.
Randomized clinical trials of cancer therapies are often conducted using survival or progression-free survival as end points. In the design of such studies sample sizes and trial durations are usually fixed, using power calculations of the type tabulated by Machin and Campbell (1987) . Sequential designs, involving a series of interim analyses with the potential for reducing sample size and trial duration, are being used increasingly in cancer survival studies (Whitehead, 1993; Fayers et al, 1994) , although concern has been expressed over their inappropriate use (Souhami, 1994) . Trial reports usually present Kaplan-Meier curves (Kaplan and Meier, 1958) and use the log-rank test (Peto et al, 1977) or Cox's regression analysis (Cox, 1972) to assess treatment differences.
The limitations of these methods, and their dependence on modelling assumptions, are well known to statisticians. These issues are explained in technical terms in introductory texts on survival analysis (see for example Collett, 1994; Parmar and Machin, 1995) . However, such limitations are not fully appreciated by many readers, or indeed writers, of clinical trial reports. The purpose of this paper is to illustrate the potential pitfalls of survival analysis in a less technical manner, through the detailed reanalysis of a particular dataset. A computer program is introduced that can be useful in demonstrating these issues to students and to others working in the field of clinical cancer research.
The issues that concern us relate to the lack of appreciation of the uncertainty inherent in sample size calculations and Kaplan-Meier curves, of their instability when the number of events is small and of the influence of the timing of a statistical analysis on the conclusions that may be drawn from a study. The accuracy of sample size calculations and the role of timing of analysis are related to an assumption that underlies most survival analysis methodologies, i.e. that of proportional hazards. This assumption is described in detail in the next section. Subsequently data from a completed trial in breast cancer are introduced and subjected to a series of analyses to demonstrate the effects of timing. The option of conducting a mid-study review to reassess the validity of proportional hazards and the number of patients required is illustrated. Finally, simple methods for checking the proportional hazards assumption are presented, and the issues raised in the paper are discussed.
THE PROPORTIONAL HAZARDS ASSUMPTION
The term proportional hazards has a precise mathematical definition that is difficult to explain in non-technical terms. Its essential meaning is easier to understand. Suppose that treatment A is more effective than treatment B. Suppose also that the event rate on treatment A is lower than that on B for the initial phase of followup (soon after the start of treatment) and for an intermediate phase also; in addition, long-term prognosis is better. Treatment A wins over every phase of follow-up, and (in some mathematical sense) it wins to the same extent. This is proportional hazards. A counter example might be a comparison of a surgical procedure (A) with chemotherapy (B). Because of operative mortality, A might be associated with a higher death rate in the short term, this being compensated by fewer deaths during the intermediate phase and a better long-term prognosis. Such a situation clearly violates the assumption of proportional hazards as A does not win over every phase of follow-up.
If it is assumed that the hazards of an event on treatments A and B are proportional, then evidence of reduced mortality on A during the immediate post-randomizaton phase will imply that A has medium and long-term benefits as well. Thus, under this assumption of proportional hazards, data from a large number of subjects who are followed for a short time will be regarded as being as informative as data from a few subjects treated for a long time. If survival times tend to be short, then in the absence of any contradictory medical features of the treatments, a proportional hazards assumption might be appropriate. For comparisons of the long-term effects of therapy, the assumption should be used with caution. Figure 1 The overall survival of (A) patients randomizei therapy or no hormone therapy (log-rank x2 = 3.56, P = 0 patients randomized to chemotherapy or no chemotheral %2 = 1.74, P = 0.19). HT, hormone therapy When the assumption of proportional hazard, approximately, methods based on this assumpti cient analysis and a simple quantification of ber single measure, i.e. the hazard ratio. Estimate intervals can be calculated for this quantity and its value can be tested. Roughly speaking, the ratio of the risk of an event during a short pei using treatment A to that using treatment B. advantageous then this ratio will be less than hazards remain proportional will this ratio be periods of follow-up. If or late during follow-up, it is the patient time scale that is being considered. The other scale is study time, which is the time since the start of the clinical trial at which an analysis is performed. Analyses are classified as early or late on this scale. The two time scales are connected in that an early analysis will concern exclusively evidence from early events during follow-up, whereas a late analysis will include events covering a wide range of times since randomization. Patients were randomized to receive radiotherapy alone, radiotherapy followed by chemotherapy, radiotherapy followed by hormone therapy or radiotherapy followed by both chemotherapy and hormone therapy. Further details and the results of this completed study were published in 1989 (Rubens et al, 1989) , and the stopping of the study is discussed in a later paper (Sylvester et al, 1994) . The trial design required analysis of the results after the admission of a minimum of 330 patients. The published analysis was conducted 8 years from the start of the study. Data from 363 evaluable patients, extracted in March 1988 from the database, were used for the published analysis. Interim analyses had been undertaken as deemed necessary by the trial committee. Figure 1 shows the survival curve estimates derived from the In Figure 3 , we show the X2 values from each of the successive analyses of hormone therapy computed from the log-rank test. Certain reference P-values are indicated by horizontal lines. A benefit of hormone therapy is suggested temporarily, 2 years into the study. Significance then disappears, followed by a slow rise in the value of X2 from 4 years to the final analysis at which there is a highly significant P-value. This progress is not steady, with a brief temporary fall in x2 just before 8 years. By chance, it was just at this point that the trial was analysed and the results presented. Figure 4 shows the estimated hazard ratio and its associated confidence limits to illustrate the precision of these estimates for each of the successive analyses. Until 4 years into the study, these values fluctuate greatly, after which they assume more constant values. These graphical representations show the inherent instability of the estimated survival curves, especially during the early phases of a trial. Similar effects are seen for the chemotherapy comparison. In Figure 5 , the series of curves for the serial analyses every 30 days are shown for patients receiving or not receiving chemotherapy. The false plateaux and variability of the curves are even more apparent than in the hormone therapy comparison. The X2 values for the corresponding log-rank tests are shown in Figure 6 . It can be seen that there is a generally rising trend towards statistical significance from 2 to 5 years after the trial started. In fact an informal interim analysis at this stage almost led to discontinuation of the study (Sylvester et al, 1994) , although it must be remarked that none of the commonly used sequential designs would have led to stopping. This trend is reversed at 6 years and, at the final 10-year (August 1989) analysis, there is no conventionally significant difference between the two treatments. Figure 7 shows the estimates and confidence limits for hazard ratio; values only achieve stability after 6 years of the study. If an analysis using evaluable patients had been some of the time points between 3 and 5 years aftei of the trial, chemotherapy would have been found tc icant effect, with a hazard ratio estimated to Hormone therapy would have been non-significant ratio estimated to be about 0.8. This is in con published analysis in which chemotherapy was stal significant benefit. It also differs from the final which again found no significant chemotherapy e showed hormone therapy to be significantly benefic How can lack of proportionality of hazards be asses mated hazards for each of six intervals of patient ti for hormone therapy ( Figure 8A ) and chemotherap Also presented are the hazard ratios (hormon hormone therapy and chemotherapy-no chemothern intervals were chosen in advance so as to include equal numbers of deaths. The final Kaplan-Meier p shows a steady advantage of hormone therapy witi endorsed by the hazard plot ( Figure 8A ) in which in hazard as a result of hormone therapy is pres similar magnitude in each of the six time intervals. The final Kaplan-Meier plot in Figure 5 shows a survival advantage for the chemotherapy group for the first 2 years of treatment, which narrows during the 3rd and 4th year and then widens again. The corresponding hazard plot ( Figure 8B) shows that, during that middle portion, the death rate on chemotherapy actually exceeds r-"----------_ that without chemotherapy. Far from being proportional over time, the hazard ratio for each time period fluctuates from favouring the chemotherapy group to favouring no chemotherapy and back again -. --over the course of follow-up.
THE COMPLETED TRIAL
There is a relationship between the plots in Figures 6 and 8B . Note that Figure 6 is plotted in study time, while Figure 8B is in patient time. Early in the study, only short-term follow-up data are -+----------, available for all patients. The short-term advantage of chemo- 8 10 therapy predominates. The X2 value is therefore high, and the hazard ratio estimate is small. Later, the data include patients in the middle th 95% Cl part of their therapy, at which time patients on chemotherapy are 3motherapy dying more rapidly than those on the control arm. The x2 value falls, and the hazard ratio estimate rises. Finally, data from late therapy also join the analysis, and the X2 values stabilize.
i performed at Plots such as those shown in Figure 8 are simple but useful r the inception checks of the assumption of proportional hazards. A more formal have a signifstatistical test of the assumption based on similar ideas is described be about 0.6.
by Bolland and Whitehead (in preparation) , together with alternawith a hazard tive forms of analysis if the assumption fails. These methods do trast with the suffer the limitation of being dependent on the choice of time ted to have no periods into which the follow-up is split. These intervals should trial analysis, have some medical relevance and be specified before the study. -ffect but also More sophisticated statistical alternatives are mentioned in that ial.
paper. If model checking confirms that the assumption of propor-100 different tional hazards is at least approximately valid, then conventional a result of the survival analyses can be confidently presented. ates of hazard Model checking before the application of an analysis that -nce intervals, depends on proportional hazards is important. However, if the There are also sample size and trial duration have been fixed by power considerrandom variaations arising from the proportional hazards model, checking after ich of the estirecruitment has closed may come too late. It may reveal that or 7) is most hazards are not proportional and that the size and duration of the as all assume study are inadequate. For this reason, it might be wise to perform a -ity of the esticheck of proportional hazards as part of a mid-study review while he hazards not the trial is still open to recruitment. Such an approach enables the produce tranprevention of such mistakes by allowing the study to be extended later but more if necessary. This bears resemblance to the ideas of Gould (1992) a will fluctuate in the simpler context of trials with success or failure as the ,the estimated primary response. ver the mix of For illustration, a mid-study review was conducted on the EORTC data as available on 1 June 1984, approximately 4.5 years after its inception. By this time, there were data for 296 evaluable patients, of whom 83 had died. Analysis of the data available at the mid-study review using the conventional log-rank test revealed that chemotherapy had a significant advantage (%2 = 4.86, P = ssed? The esti-0.028). The corresponding estimate of the hazard ratio for ime are shown chemotherapy relative to placebo was 0.62 with 95% confidence y ( Figure 8B ). interval 0.40-0.95. For hormone therapy, the log-rank test revealed ie therapy-no that hormone therapy had no significant effect (X2 = 1.21, P = apy). The time 0.271), resulting in a hazard ratio of 0.78 with 95% confidence approximately interval 0.51-121. )lot in Figure 2 At the mid-study review, we also performed graphical model h time. This is checking of the assumption of proportional hazards using the estithe reduction mated hazards for four periods of patient time. For hormone sent and is of therapy, the hazard ratio favoured treatment in each time period.
British Journal of Cancer (1997) However, for chemotherapy, the hazard ratio was favourable for treatment for the first 14-month time interval of the trial and was less favourable for the 14 to 22-month interval. In the third interval from 22 to 28 months, the death rate on chemotherapy exceeds that on no chemotherapy, but it returns to favouring chemotherapy in the fourth interval, 29-40 months. The hazard ratio is therefore far from being proportional. Careful consideration might be given at this stage to the adequacy of the planned sample size and the duration of follow-up for the trial. Plans for interim analyses and stopping rules could also be revised. Peto et al (1977) popularized the methodology among medical researchers. The log-rank test is a significance test of the equality of the two survival distributions. The significance level is calculated under the null hypothesis of equality and does not depend on the form of the common survival distribution. Thus, it is non-parametric as it does not depend on any distributional assumptions. The log-rank test makes efficient use of the data only if the proportional hazards assumption is valid. This means that the test will have high power to detect a constant hazard ratio not equal to one. If a treatment was associated with a higher death rate in the short-term but had a good longer-term prognosis compared with control, then the hazards would be non-proportional; in fact they would cross. This would lead to a log-rank test with a X2 value close to zero, incorrectly indicating no treatment effect.
DISCUSSION
Unless the assumption of proportional hazards is valid, the timing of an analysis can have a substantial effect on its conclusion, as we have demonstrated. The quotation of a single hazard ratio estimate from a survival study obviously presupposes at least approximate proportionality of hazards. Otherwise the trial findings have to be summarized through a series of hazard ratio estimates pertaining to different patient-time intervals or using some other non-constant presentation. Cox's regression analysis allows more complicated modelling, but it still relies on an assumption of proportional hazards and, when applied to two treatments in the absence of other covariates, it is essentially the same as the logrank test.
For the trialist, the assumption of proportional hazards presents difficulties. Conventional calculations of sample size and study duration for survival trials are based on the proportional hazards assumption (Freedman, 1982; Machin and Campbell, 1987) . Sequential designs tend also to require this assumption (Whitehead, 1993) . The assumption of proportional hazards needs careful consideration at the design stage. Model checking of previous trials may cast doubts on its validity. Consideration of the mode of action of an experimental treatment might indicate, for example, that short-term mortality will be increased as the price for long-term benefit or, conversely, that benefits will affect shortterm survival and quality of life but not the chances of survival beyond 1 year. In either case the assumption of proportional hazards is likely to be incorrect. An alternative summary measure of treatment advantage must be sought -not the (assumed constant) hazard ratio but perhaps the ratio of odds on survival past 1 year or the 'averaged' hazard ratio over 1 year. Calculations of sample size and study duration, and sequential methods can be based on these alternative measures. Either of the choices above will lead to studies requiring a substantial number of patients with at least 1 year of follow-up, or to sequential designs in which stopping is impossible before data on patients who have completed the whole of the 1st year of treatment begin to accumulate. In some diseases, it may be necessary to substitute 5 years for 1 year. Unless there are disastrous short-term results, these will have to be long studies, even if a sequential design is used.
In some cases, absolutely nothing will be known about the likely form of hazard ratios. The proportional hazards assumption perhaps leads to the default design. Post-trial model checking may either confirm this assumption or indicate that a further trial with a more suitable design is necessary. It is wise to plan for a long follow-up period if possible, especially if therapy is short term and irreversible (e.g. surgery) rather than long term with potential continuous harm (e.g. life-long drug therapy). This will allow any late evidence of treatment effect and of non-proportionality of hazards to emerge. We have shown how a mid-study review might be used so that the trial design might be revised to take account of emerging evidence about relative hazards. Such a review could be used as a prospective tool in a clinical trial -but caution is needed. First, at this relatively early stage, there will be little power to detect even serious departures from proportional hazards as being significant, and conversely misleadingly clear but non-significant patterns might arise. Second, as the review is not blind to treatment it could reveal such large survival differences that the trial has to be stopped. Rather than ignoring the latter possibility, it may be best to incorporate the review as the first (and possibly only) look within a formal sequential design. This will protect against inflation of risks of error and, in the case of pharmaceutical trials, satisfy regulatory requirements. We are not, on the other hand, going so far as to urge formal allowance for repetition of the model checking nor for its own effects on the final analysis.
If model checking confirms that the assumption of proportional hazards is at least approximately valid, then conventional analyses can be confidently presented; if serious departures from proportional hazards are present, then the situation is less clear. Few alternative methods have been extensively discussed in the statistical literature (Kalbfleisch and Prentice, 1981; Pepe and Fleming 1989) .
The variability of data, especially early in a trial, and the fact that hazards may not be proportional means that clinicians must be cautious about accepting trial results at face value, especially when large early differences have led to early stopping of a study. Data monitoring committees in particular should be exceedingly cautious about stopping randomized trials when early effects occur, even if clearly significant by conventional tests. We can be more confident of a result when the trial size is very large and the follow-up time is long. Alas, this competes with other priorities in clinical research, such as the need to complete trials quickly and the need to ask the next, and most urgent, question.
